BRIEF published on 03/25/2025 at 06:05, 1 year ago SKAN Records Significant Profit and Order Growth in 2024 Sustainability Strategy Order Intake Increase EBITDA Margin Expansion SKAN Group Financial Growth Future Growth Investments
PRESS RELEASE published on 03/25/2025 at 06:00, 1 year ago SKAN with significant profit increase and strong order intake in the 2024 financial year SKAN reports significant profit increase and strong order intake in the 2024 financial year, with growth in order intake, net sales, and EBITDA. Dividend proposed at CHF 0.40 per share Financial Year Dividend Order Intake Profit Increase SKAN
BRIEF published on 01/22/2025 at 07:05, 1 year 2 months ago SKAN Reports Preliminary Figures for 2024 EBITDA Pharmaceutical Industry Net Sales SKAN Group AG 2024 Financial Figures
PRESS RELEASE published on 01/22/2025 at 07:00, 1 year 2 months ago SKAN announces preliminary key figures for the 2024 financial year SKAN Group AG announces preliminary key figures for the 2024 financial year revealing increased net sales and EBITDA. Detailed financial results will be released on March 25, 2025 EBITDA Net Sales 2024 Financial Year SKAN Group AG Preliminary Key Figures
BRIEF published on 08/20/2024 at 07:05, 1 year 7 months ago SKAN Group Reaches Its Targets in the First Half of 2024 Profitability Net Sales Growth Order Intake Half-year Results SKAN Group
PRESS RELEASE published on 08/20/2024 at 07:00, 1 year 7 months ago SKAN Group reaches its targets in the first half of 2024 SKAN Group AG achieves targets with net sales growth of 17.2% and EBITDA increase of 15.7% in the first half of 2024. Strong order intake and backlog, confirming guidance for full year Net Sales Growth Order Intake EBITDA Increase Guidance SKAN Group
BRIEF published on 05/31/2024 at 07:05, 1 year 9 months ago SKAN Increases Stake in Aseptic Technologies to 90 Percent Pharmaceutical Industry Stake Increase SKAN Aseptic Technologies AT-Closed Vial®
PRESS RELEASE published on 05/31/2024 at 07:00, 1 year 9 months ago SKAN increases stake in Aseptic Technologies to 90 percent SKAN Group AG increases its stake in Aseptic Technologies to 90%, reinforcing strategic importance. Aseptic Technologies specializes in AT-Closed Vial® Technology for cell and gene therapy applications Pharmaceutical Industry Stake Increase SKAN Group AG Aseptic Technologies AT-Closed Vial® Technology
BRIEF published on 05/07/2024 at 18:05, 1 year 10 months ago SKAN Group AG's Annual General Meeting: Unanimous Approval of Proposals, Beat Lüthi Elected Chairman Annual General Meeting Shareholder Approval Dividend SKAN Group AG Chairman Election
PRESS RELEASE published on 05/07/2024 at 18:00, 1 year 10 months ago Annual General Meeting of SKAN Group AG approves all pro-posals and elects Beat Lüthi as Chairman SKAN AG Annual General Meeting approves all proposals and elects Beat Lüthi as Chairman. Distribution of CHF 0.35 dividend per share approved, next AGM on 5 May 2025 Board Of Directors Annual General Meeting Dividend Distribution SKAN AG Beat Lüthi
Published on 03/26/2026 at 22:05, 20 minutes ago BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 25 minutes ago Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 25 minutes ago Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 1 hour 25 minutes ago Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/26/2026 at 21:00, 1 hour 25 minutes ago Rocky Shore Closes Acquisition of Additional Mining Claims
Published on 03/26/2026 at 20:48, 1 hour 37 minutes ago Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 3 hours 5 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 3 hours 16 minutes ago 2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:17, 4 hours 8 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 07:30, 14 hours 55 minutes ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
